A Selective PPARγ Modulator Reduces Hepatic Fibrosis.
Benita L McVickerFrederick G HamelRonda L SimpsonRobert G BennettPublished in: Biology (2020)
Hepatic fibrosis is the accumulation of excess collagen as a result of chronic liver injury. If left unabated, hepatic fibrosis can lead to the disruption of the liver architecture, portal hypertension, and increased risk of progression to cirrhosis and hepatocellular carcinoma. The thiazolidinedione class of antidiabetic drugs, through their target peroxisome proliferator-activated receptor γ (PPARγ), have protective effects against liver fibrosis, and can inhibit the profibrotic activity of hepatic stellate cells, the major collagen-producing liver cells. However, these drugs have been ineffective in the treatment of established fibrosis, possibly due to side effects such as increased weight and adiposity. Recently, selective PPARγ modulators that lack these side effects have been identified, but their role in treating fibrosis has not been studied. In this study, we tested the effectiveness of one of these selective modulators, SR1664, in the mouse carbon tetrachloride model of established hepatic fibrosis. Treatment with SR1664 reduced the total and type 1 collagen content without increasing body weight. The abundance of activated hepatic stellate cells was also significantly decreased. Finally, SR1664 inhibited the profibrotic phenotype of hepatic stellate cells. In summary, a selective PPARγ modulator was effective in the reduction of established hepatic fibrosis and the activated phenotype of hepatic stellate cells. This may represent a new treatment approach for hepatic fibrosis.
Keyphrases
- induced apoptosis
- liver fibrosis
- cell cycle arrest
- liver injury
- drug induced
- body weight
- insulin resistance
- small molecule
- cell death
- blood pressure
- endoplasmic reticulum stress
- signaling pathway
- systematic review
- oxidative stress
- type diabetes
- physical activity
- fatty acid
- skeletal muscle
- replacement therapy
- wastewater treatment
- antibiotic resistance genes